Systemic lupus erythematosus and antineutrophil cytoplasmic antibody—associated vasculitis: An emerging overlap syndrome with cutaneous manifestations

Paul Curtiss, BA, Tracey Liebman, MD, Ciril Khorolsky, MD, Nooshin Brinster, MD, Jenna Beasley, MD, and Kristen Lo Sicco, MD

New York and Brooklyn, New York

Key words: antineutrophil cytoplasmic antibody; renal failure; systemic lupus erythematosus; vasculitis.

INTRODUCTION

Systemic lupus erythematosus and antineutrophil cytoplasmic antibody (ANCA)—associated vasculitis (SLE/AAV) overlap syndrome is a rare disease originally described in 2008. With only a few reports in the literature, this condition is characterized by aggressive crescentic glomerulonephritis, arthritis, cutaneous involvement, and both antinuclear antibody (ANA) and ANCA. Dermatologic manifestations are common and may occur at initial presentation. Although skin lesions may vary in morphology, the most commonly reported include cutaneous nodules and ecchymoses. Few reports have characterized the cutaneous findings seen in this disorder. We report a young woman with SLE/AAV overlap syndrome who presented with a macular eruption and histopathology findings demonstrating interface dermatitis.

CASE

A 40-year-old woman with a history of hypertension presented with headache, right-sided weakness, and acute renal failure. Computed tomography of the head showed subarachnoid hemorrhage caused by aneurysm rupture that was successfully treated with endovascular coil embolization. Renal ultrasound scan found intrinsic renal disease, and rheumatologic workup was significant for positive antinuclear antibody (anti-MPO) antibody titer (perinuclear ANCA [p-ANCA]) of 8 IU/mL, ANA with a nucleolar pattern at a titer of 1:640, antichromatin IgG of 1.7 IU/mL and ribonucleoprotein (RNP) antibody of 5.3 IU/mL. Anti-ro, anti-la, anticycliccycldiolipin antibody, and lupus anticoagulant were negative. Her creatinine continued to increase (maximum 8.7), and she ultimately required hemodialysis. Renal biopsy with immunofluorescence found pauci-immune crescentic and necrotizing glomerulonephritis. There was no evidence of endocapillary proliferation or immune complex deposition.

Abbreviations used:

AAV: antineutrophil cytoplasmic antibody—associated vasculitis
ACR: American College of Rheumatology
ANA: antinuclear antibody
ANCA: antineutrophil cytoplasmic antibody
anti-MPO: antimyeloperoxidase
MCTD: mixed connective tissue disease
p-ANCA: perinuclear antineutrophil cytoplasmic antibody
RNP: ribonucleoprotein
SLE/AAV: systemic lupus erythematosus
antineutrophil cytoplasmic antibody—associated vasculitis overlap syndrome

From The Ronald O. Perelman Department of Dermatology, New York University School of Medicine* and the Department of Internal Medicine, NYU Lutheran Medical Center.

Funding sources: None.

Conflicts of interest: None disclosed.

Correspondence to: Kristen Lo Sicco, MD, FAAD, The Ronald O. Perelman Department of Dermatology, 240 East 38th Street, 11th Floor, New York, New York 10016. E-mail: Kristen.LoSicco@nyumc.org.
During her hospitalization, the patient developed numerous pruritic cutaneous lesions for which the dermatology department was consulted. Physical examination found well-demarcated annular hyperpigmented patches with peripheral erythema and central duskiness on her trunk and extremities (Fig 1). The eruption was not photodistributed. The remainder of her skin and mucosal examination was otherwise unremarkable.

A punch biopsy found interface dermatitis with slight basement membrane thickening and no increased mucin deposition (Fig 2). Direct immunofluorescence from lesional skin on the right arm was positive for granular C3 deposition along the dermoepidermal junction, and IgG demonstrated intraepidermal in vivo ANA. IgA, IgM, and fibrinogen were negative. Based on her clinical and pathologic findings, the diagnosis of SLE/AAV overlap syndrome was made.

Systemic therapy was started primarily to treat her refractory kidney disease and consisted of prednisone, rituximab, hydroxychloroquine, and cyclophosphamide. Additionally, the patient received 1 week of plasma exchange. Cyclophosphamide was poorly tolerated, and she was ultimately transitioned to azathioprine. She was also treated with triamcinolone 0.1% cream twice daily. Her cutaneous involvement and pruritus resolved, although renal failure persisted, requiring continued hemodialysis.

**DISCUSSION**

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease mediated by autoantibody deposition against a variety of targets, including ANA. AAV is a systemic vasculitis mediated by antibodies targeting the granules in polymorphonuclear leukocytes, most commonly anti-MPO or anti-proteinase 3. Although ANCA antibodies occur in approximately 16% of patients with SLE, it is unclear whether this serologic finding is of clinical significance, as few of these patients have concomitant ANCA-associated vasculitis. Furthermore, nonspecific assays for ANCA may cross react with ANAs because of an artifact in ethanol fixation, potentially confounding any true associations.

Distinguishing ANCA vasculitis from SLE vasculitis may, as SLE vasculitis occurs in 11% to 35% of SLE patients, and can manifest in small, medium, and large vessels. SLE vasculitis typically occurs in established SLE patients in the context of a disease flare and is generally mediated by complement and immune complex deposition. The underlying renal histopathology may help to distinguish the diseases. SLE glomerulonephritis often shows immune complex deposition on the glomerular basement membrane. In exception, type IV segmental renal vasculitis does not demonstrate the classic features of lupus nephritis, as it is pauci-immune and resembles ANCA vasculitis both clinically and pathologically. These distinct features lead to the
hypothesis of an overlapping syndrome between SLE and AAV.

In 2008, Nasr and colleagues\(^1\) reported a series of 10 patients who presented with severe necrotizing crescentic glomerulonephritis and were all found to be ANCA positive.\(^1\) Renal biopsies exhibited a pattern consistent with lupus nephritis and AAV. The major histopathologic features of these cases (fibrinoid necrosis, absence of significant immune complex deposition, absence of endocapillary proliferation) mirror our patient’s renal biopsy. Eight of the 10 patients met American College of Rheumatology (ACR) diagnostic criteria for definite SLE; the other 2 patients met criteria for probable SLE. These findings suggested the existence of an overlapping syndrome of what were previously SLE and AAV. In 2012, another small case series was published of 4 patients with features of both lupus nephritis and AAV, all of whom were positive for anti-MPO (p-ANCA) antibodies, further corroborating the existence of an overlap syndrome.\(^12\)

In a meta-analysis of published literature, Jarrot and colleagues\(^2\) identified 39 patients who met diagnostic criteria for both SLE and AAV, 38 of whom presented with necrotizing crescentic glomerulonephritis.\(^2\) Forty-three percent of these patients had cutaneous lesions. The most commonly reported cutaneous findings were ecchymoses and skin nodules but also included livedo reticularis, Raynaud phenomenon, alopecia, and a malar eruption. There were no descriptions of dusky targetoid patches as were seen in our patient.

Given the small number of reports in the literature, the SLE/AAV overlap syndrome is still being defined but carries features of both diseases. As many as 70% of patients carry no diagnosis of SLE or AAV before presentation.\(^2,12\) Ninety percent of the cases occur in women, with a mean age in the fourth decade.\(^2,12\) The most common features of the overlap syndrome include arthritis, serositis, cytophenias, rhinosinusitis, and pulmonary hemorrhage.\(^1,2,12\) Rapidly progressive glomerulonephritis is an almost universal feature.\(^1,2,12,13\) Several cases report central nervous system vasculitis and thrombotic cerebrovascular events.\(^2,12,13\) We identified no previous reports of cerebral aneurysm or intracranial hemorrhage, as with our patient. The most common systemic treatments are corticosteroids and cyclophosphamide.\(^1,2,12\)

Our patient had 3 ACR criteria for SLE including cutaneous lupus, glomerulonephritis, and elevated ANA titers. Four ACR criteria are typically met before a definitive SLE diagnosis is made. Although elevated double-stranded DNA was absent in our patient, she did have antichromatin IgG, which is a relatively specific marker for SLE although not included in ACR criteria.\(^14\) Other reported cases also met only 3 ACR criteria for lupus when they presented with SLE/AAV overlap syndrome.\(^\text{1}^1\) Although our patient had an elevated RNP, which is a feature of undifferentiated connective tissue disease or mixed connective tissue disease (MCTD) she showed no other features of MCTD such as Raynaud phenomenon or inflammatory myopathy. Rarely, RNP-positive MCTD has been associated with microscopic polyangiitis and rapidly progressive glomerulonephritis.\(^15\) These patients carried a diagnosis of MCTD for between 8 months and 19 years before symptoms of ANCA vasculitis developed.

Our patient’s age, gender, and clinical and histopathologic renal disease were all typical of SLE/AAV syndrome. Her treatment plan targeted her ultimately refractory kidney disease, and although her skin lesions improved, it is unclear if one therapy showed superiority over another. Further clinical and pathologic documentation and characterization of SLE/AAV overlap syndrome is important to help elucidate the pathologic mechanisms driving this rare but potentially devastating disease.

REFERENCES

1. Nasr SH, D’Agati VD, Park H-R, et al. Necrotizing and crescentic lupus nephritis with antineutrophil cytoplasmic antibody seropositivity. *Clin J Am Soc Nephrol*. 2008;3:682-690.
2. Jarrot PA, Chiche L, Hervier B, et al. Systemic lupus erythematosus and antineutrophil cytoplasmic antibody-associated vasculitis overlap syndrome in patients with biopsy-proven glomerulonephritis. *Medicine*. 2016;95:e3748.
3. Ippolito A, Wallace DJ, Gladman D, et al. Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity. *Lupus*. 2011;20:250-255.
4. Csernok E. Anti-neutrophil cytoplasmic antibodies and pathogenesis of small vessel vasculitides. *Autoimmun Rev*. 2003;2:158-164.
5. Chen M, Zhao MH, Zhang Y, Wang H. Antineutrophil autoantibodies and their target antigens in systemic lupus erythematosus. *Lupus*. 2004;13:584-589.
6. Galeazzi M, Morozzi G, Sebastiani GD, et al. Anti-neutrophil cytoplasmic antibodies in 566 European patients with systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies. European Concerted Action on the Immunogenetics of SLE. *Clin Exp Rheumatol*. 1998;16:541-546.
7. Manolova I, Dancheva M, Halacheva K. Antineutrophil cytoplasmic antibodies in patients with systemic lupus erythematosus: prevalence, antigen specificity, and clinical associations. *Rheumatol Int*. 2001;20:197-204.
8. Lee SS, Lawton JW, Chak W. Distinction between antinuclear antibody and P-ANCA. *J Clin Pathol*. 1991;44:962-963.
9. Barile-Fabris L, Hernandez-Cabrera MF, Barragan-Garfias JA. Vasculitis in systemic lupus erythematosus. *Curr Rheumatol Rep*. 2014;16:440.
10. Jennette JC, Thomas D. Crescentic glomerulonephritis. *Nephrol Dial Transplant*. 2001;16:80-82.
11. Tsumagari T, Fukimoto S, Kinjo M, Tanaka K. Incidence and significance of intrarenal vasculopathies in patients with systemic lupus erythematous. *Hum Pathol*. 1985;16:43-49.

12. Hervier B, Hamidou M, Haroche J, Durant C, Mathian A, Amoura Z. Systemic lupus erythematous associated with ANCA-associated vasculitis: an overlapping syndrome? *Rheumatol Int* 2012;32:3285-3290.

13. Cavagna L, Caporali R, Esposito C, Augetti C, Epis O, Montecucco C. Clinical features of ANCA-positive systemic lupus erythematous: report of two cases. *Scand J Rheumatol*. 2007;36:74-76.

14. Schett G, Smole J, Zimmermann C, et al. The autoimmune response to chromatin antigens in systemic lupus erythematous: autoantibodies against histone H1 are a highly specific marker for SLE associated with increased disease activity. *Lupus*. 2002;11:704-715.

15. Tubery A, Fortenfant F, Combe B, et al. Clinical association of mixed connective tissue disease and granulomatosis with polyangiitis: a case report and systematic screening of anti-U1RNP and anti-PR3 auto-antibody double positivity in ten European hospitals. *Immunol Res.* 2016;64:1243-1246.